MetaCap

Cypherpunk Technologies (CYPH) vs Immuneering (IMRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cypherpunk Technologies (CYPH) has outperformed Immuneering (IMRX) over the past year, losing 38.2% versus a loss of 53.7%. Over five years, IMRX leads with a -85.0% price change compared with -94.4% for CYPH. Immuneering is the larger company by market cap ($218.9 million vs $210.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CYPH-38.16%IMRX-53.70%
+89%+2%-85%
Nov 21, 20251 yearNov 20, 2026
CYPH-93.79%IMRX-86.40%
+50%-28%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CYPH versus IMRX key metrics
MetricCYPHIMRX
Share price$1.41$3.38
Market cap$210.15M$218.90M
1-day change-18.02%-2.03%
YTD return+21.55%-48.63%
1-year return-38.16%-53.70%
5-year return-94.45%-85.00%
P/E ratio (TTM)0.67—
EPS (TTM)$2.09$-0.92
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$4.82M$-56.02M
52-week high$4.19$8.48
52-week low$0.491$3.29
Distance from 52-week high-66.35%-60.14%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+254.61%+402.96%
Average volume15.42M747.66K
Shares outstanding149.04M64.76M
Employees665
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CYPH has outperformed IMRX by 15.5 percentage points over the past year.

About Cypherpunk Technologies

CYPH stock →

Cypherpunk Technologies Inc., a privacy technology company, implements a digital asset strategy anchored by Zcash in the United States. The company is involved in identifying, developing, investing in, acquiring, and building privacy-enhancing technologies; and accumulating digital assets, such as ZCash.

Health Care · Biotechnology: Pharmaceutical Preparations · 6 employees

About Immuneering

IMRX stock →

Immuneering Corporation, a late-stage oncology company, develops medicines for broad populations of cancer patients in the United States. The company develops IMM-1-104 (atebimetinib), a dual-MEK inhibitor that is in a Phase 3 clinical trial to treat patients with cancer, including pancreatic and non-small cell lung cancer caused by mutations of RAS or RAF; IMM-6-415 (envometinib), which is in Phase 1/2a clinical trial for the treatment of patients with solid tumors; and multiple deep cyclic inhibitor discovery programs.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

CYPH vs IMRX FAQ

Which is bigger, Cypherpunk Technologies or Immuneering?

Immuneering (IMRX) is larger, with a market capitalization of $218.90M compared with $210.15M for Cypherpunk Technologies (CYPH).

Which stock has performed better over the past year, CYPH or IMRX?

CYPH returned -38.16% over the past 12 months, compared with -53.70% for IMRX (price return, excluding dividends). Past performance does not predict future results.

Are Cypherpunk Technologies and Immuneering in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons